Latest Health News

Mayne Pharma reports a robust first half of FY25 with revenues climbing to $210-$215 million and underlying EBITDA soaring by up to 300%, driven by strong performance in Women's Health.

Smartgroup has been appointed as the exclusive provider of salary packaging and novated leasing services for Monash Health’s 25,000 employees under a new multi-year contract starting April 2025.

JB Hi-Fi Limited reported a robust half-year performance for the period ending December 31, 2024, with revenue up 9.9% and net profit rising 8.1%, underpinned by strong segment contributions and a strategic acquisition. The company declared a healthy interim dividend of 170 cents per share, signalling confidence in its financial position.

Sigma Healthcare has raised its FY25 normalised EBIT guidance to $64-$70 million, driven by robust operational performance and the successful rollout of a key supply contract with Chemist Warehouse.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

TMK Energy has reported a staggering 300% increase in gas production in January 2025, setting a new monthly record driven by newly commissioned wells at its Gurvantes XXXV Coal Seam Gas Project.

ImpediMed Limited has locked in a US$15 million growth capital facility with SWK Funding LLC, providing crucial financial flexibility to advance its SOZO Digital Health Platform and commercial ambitions.

Beach Energy Limited has announced a fully franked ordinary dividend of AUD 0.03 per share for the half-year ending December 2024, payable on March 31, 2025.

The Calmer Co. International Limited has secured a FJD2.64 million loan from Fiji Development Bank to acquire its Navua manufacturing site, marking a strategic step to enhance production and market presence in the global kava industry.

Beach Energy has reported a robust first half of FY25, marked by a 37% increase in underlying earnings and significant progress on key projects including the Waitsia Gas Plant commissioning and Moomba CCS. The company’s strong operational performance supports a 50% increase in its interim dividend.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.